HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...
Combining CEUS with pre-ablation MR or CT images improved clinicians’ ability to delineate tumor borders and detect RCC recurrence after percutaneous ablation. CEUS images were successfully fused with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results